- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Mar 26, 2021
Highlights
- Market Cap
- $61.10B
- Enterprise Value
- $61.03B
- EPS (TTM)
- -$0.02
- Gross Profit (TTM)
- -$606.00K
- EBITDA (TTM)
- -$53.13M
- Year Range
- $3.94 - $18.00
- Target Price
- $1.33
- ROA (TTM)
- -32.98%
- ROE (TTM)
- -36.55%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
IMA Performance Chart
ImageneBio, Inc (IMA) is down 21.0% since the beginning of the year. At $5 per share, IMA is trading 69.7% below its 52-week high of $18. Investors who bought $1,000 worth of IMA shares 5 years ago would now be looking at an investment worth $29.
Loading charts...
Returns By Period
ImageneBio, Inc (IMA) has returned -21.01% so far this year and -66.36% over the past 12 months.
ImageneBio, Inc
- 1D
- -0.37%
- 1M
- -4.64%
- YTD
- -21.01%
- 6M
- -17.80%
- 1Y
- -66.36%
- 3Y*
- -59.37%
- 5Y*
- -50.70%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.68%
- YTD
- 11.16%
- 6M
- 11.10%
- 1Y
- 27.46%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
IMA Monthly Returns History
Based on dividend-adjusted daily data since Mar 26, 2021, IMA's average daily return is -0.15%, while the average monthly return is -3.95%.
Historically, 36% of months were positive and 64% were negative. The best month was Jan 2023 with a return of +60.2%, while the worst month was Nov 2023 at -64.0%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.
On a daily basis, IMA closed higher 43% of trading days. The best single day was Jun 24, 2022 with a return of +29.4%, while the worst single day was Nov 9, 2023 at -67.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 8.84% | -10.52% | -25.60% | 20.40% | -2.33% | -7.31% | -21.01% | ||||||
| 2025 | -9.76% | -9.46% | -4.48% | -0.78% | -6.30% | 12.61% | 11.32% | -25.14% | -39.18% | 6.87% | -20.78% | 0.00% | -64.94% |
| 2024 | -31.98% | 6.72% | -0.70% | -7.04% | 34.09% | -6.78% | 1.82% | 1.79% | 1.17% | -1.16% | 1.17% | -5.20% | -16.75% |
| 2023 | 60.15% | -5.87% | -13.97% | 58.84% | 17.70% | 1.71% | -21.49% | -9.90% | -6.68% | -6.93% | -64.02% | 35.86% | -25.94% |
| 2022 | -22.41% | -37.20% | -0.16% | -36.39% | 0.52% | 13.59% | 14.22% | -6.13% | -25.26% | -22.54% | -18.91% | 19.28% | -78.79% |
| 2021 | -11.72% | -13.38% | -26.44% | -22.00% | -29.42% | 29.87% | -1.94% | -14.82% | 33.07% | -12.34% | -60.81% |
Benchmark Metrics
ImageneBio, Inc has an annualized alpha of -40.23%, beta of 1.03, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since March 29, 2021.
- This stock participated in 182.96% of S&P 500 Index downside but only -84.49% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -40.23%
- Beta
- 1.03
- R²
- 0.04
- Upside Capture
- -84.49%
- Downside Capture
- 182.96%
Return for Risk
Risk / Return Rank
IMA ranks 8 for risk / return — in the bottom 8% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for ImageneBio, Inc (IMA) and compare them to S&P 500 Index.
| IMA | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.87 | 2.39 | -3.25 |
Sortino ratioReturn per unit of downside risk | -1.34 | 3.25 | -4.59 |
Omega ratioGain probability vs. loss probability | 0.82 | 1.43 | -0.61 |
Calmar ratioReturn relative to maximum drawdown | -0.87 | 3.11 | -3.98 |
Martin ratioReturn relative to average drawdown | -1.19 | 14.38 | -15.57 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the ImageneBio, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ImageneBio, Inc was 98.82%, occurring on Apr 6, 2026. The portfolio has not yet recovered.
The current ImageneBio, Inc drawdown is 98.58%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -98.82%Apr 2026 | 5y 9d | — | 5y 2moMar 2021 - now |
Drawdown Indicators
| IMA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.82% | -56.78% | -42.04% |
Max Drawdown (1Y)Largest decline over 1 year | -74.58% | -9.10% | -65.48% |
Max Drawdown (3Y)Largest decline over 3 years | -94.58% | -18.90% | -75.68% |
Max Drawdown (5Y)Largest decline over 5 years | -97.76% | -25.43% | -72.33% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -98.58% | 0.00% | -98.58% |
Average DrawdownAverage peak-to-trough decline | -85.56% | -10.72% | -74.84% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 54.13% | 1.97% | +52.16% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ImageneBio, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how ImageneBio, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for IMA in comparison with other companies in the Biotechnology industry. Currently, IMA has a P/B value of 495.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with IMA
Add ImageneBio, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with IMA